Important note: Information in this article was accurate in October 2004. The state of the art may have changed since the publication date.
 |
HIV Treatment Bulletin - Vol. 5, No. 9/10, October/November 2004
HIVandHepatitis.com
Predictive factors of the virologic success of the use of the protease inhibitor lopinavir/r (Kaletra) in HIV-infected children are unknown, especially in children who have been pretreated with protease inhibitors (PIs).
This longitudinal, single-centre, observational study included 69 children (21 PI-naïve and 48 PI-experienced) who had received LPV/r for at least 3 months. The mean (±SD) age was 10.3 ± 4.8 years, and the mean baseline of CD4+ T cell percentage and HIV-1 RNA was 14.9% ± 9.8% and 4.8 ± 1.05 log10 copies/mL, respectively.
The mean duration of follow-up was 16.5 ± 8.3 months.
At 6, 12, and 18 months, 52%, 57%, and 49% of all children, respectively, had a viral load less than 50 copies/mL. The risk of virologic failure, defined as two consecutive viral loads greater than 1000 copies/mL, was significantly higher when the children were previously treated with PIs and when the baseline LPV mutation score exceeded 3 mutations.
In the pretreated children, the ratio of the plasma LPV maximal concentration to the baseline LPV score mutation was also associated with failure, independently of resistance score.
Finally, in children failing an LPV-containing regimen, accumulation of additional PI-associated resistance mutations was evidenced in viral isolates from children with prior PI treatment, even with viral replication levels less than 10,000 copies/mL.
The authors conclude: “In pretreated children, LPV plasma levels should be optimised in an attempt to achieve sufficient drug concentrations to overcome the resistance level.”
Source: HIVandHepatitis.com
Ref: Delaugerre C et al. Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2004 Oct 1;37(2):1269-1275.
041010
IB040510-19
© Copyright 2004 by HIV and Hepatitis.com. All Rights Reserved. Reproduction for personal or educational use is encouraged and does not require permission. Written permission is required to re-print copyrighted articles but is almost always granted (email: publisher@HIVandHepatitis.com). ©2004. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone / Firestone Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
